Publication & Citation Trends
Publications
147 total
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Cited by 0
Semantic Scholar
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis OA
Cited by 34
Semantic Scholar
Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Cited by 0
Semantic Scholar
S1073 Clinical Outcomes and Biomarker Normalization Response at Week 16 in Patients With Inadequate Response or Intolerance to Prior Biologics in the POWER Trial OA
Cited by 0
Semantic Scholar
S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial OA
Cited by 3
Semantic Scholar
Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response during ustekinumab maintenance therapy: week 16 results from the phase 3b POWER trial
Cited by 0
Semantic Scholar
P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials OA
Cited by 0
Semantic Scholar
HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn’s Disease Patients OA
Cited by 9
Semantic Scholar
Research Topics
Inflammatory Bowel Disease
(113)
Immunodeficiency and Autoimmune Disorders
(38)
Chronic Lymphocytic Leukemia Research
(33)
Microscopic Colitis
(32)
Eosinophilic Esophagitis
(31)
Affiliations
Ben-Gurion University of the Negev
Western University
Johnson & Johnson (United States)
Janssen (Belgium)
Hospital of the University of Pennsylvania